The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $16.81

Today's change-0.06 -0.36%
Updated February 23 4:00 PM EST. Delayed by at least 15 minutes.
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $16.81

Today's change-0.06 -0.36%
Updated February 23 4:00 PM EST. Delayed by at least 15 minutes.

Ironwood Pharmaceuticals Inc down (U.S.)$0.06

Ironwood Pharmaceuticals Inc closed lower Thursday, dropping (U.S.)$0.06 or 0.36% to (U.S.)$16.81. Shares have lost 1.00% over the last five days, but sit 3.89% below their 52-week high. This security has outperformed the S&P 500 by 67.12% during the last year.

Key company metrics

  • Open(U.S.) $16.83
  • Previous close(U.S.) $16.87
  • High(U.S.) $16.95
  • Low(U.S.) $16.55
  • Bid / Ask-- / --
  • YTD % change+9.94%
  • Volume1,451,512
  • Average volume (10-day)1,191,260
  • Average volume (1-month)1,304,690
  • Average volume (3-month)1,329,860
  • 52-week range(U.S.) $8.18 to (U.S.) $17.49
  • Beta1.49
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.56
Updated February 23 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue66546653
Total other revenue--------
Total revenue66546653
Gross profit66546653
Total cost of revenue0000
Total operating expense94706859
Selling / general / administrative45373632
Research & development38323228
Depreciation / amortization31----
Interest expense (income), net operating--------
Unusual expense (income)90--0
Other operating expenses, total--------
Operating income-28-15-2-6
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-33-22-13-14
Income after tax-33-22-13-14
Income tax, total--------
Net income-33-22-13-14
Total adjustments to net income--------
Net income before extra. items-33-22-13-14
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-33-22-13-14
Inc. avail. to common incl. extra. items-33-22-13-14
Diluted net income-33-22-13-14
Dilution adjustment--------
Diluted weighted average shares145145144143
Diluted EPS excluding extraordinary itemsvalue per share-0.23-0.15-0.09-0.10
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.17-0.15-0.09-0.10